CC
Casdin Capital Portfolio holdings
AUM
$1.1B
This Quarter Return
+42.47%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$354M
AUM Growth
+$354M
(+42%)
Cap. Flow
+$47.4M
Cap. Flow
% of AUM
13.38%
Top 10 Holdings %
Top 10 Hldgs %
61.1%
Holding
34
New
–
Increased
14
Reduced
4
Closed
5
Top Buys
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$11.2M |
| 2 |
BLUE
bluebird bio
BLUE
|
$11M |
| 3 |
GNMK
GenMark Diagnostics, Inc
GNMK
|
$7.85M |
| 4 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$7.07M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$5.12M |
Top Sells
| 1 |
EPZM
Epizyme, Inc
EPZM
|
$7.85M |
| 2 |
Gilead Sciences
GILD
|
$5.31M |
| 3 |
AMRS
Amyris Inc.
AMRS
|
$1.59M |
| 4 |
TSRO
TESARO, Inc.
TSRO
|
$1.23M |
| 5 |
Pacific Biosciences
PACB
|
$1.07M |
Sector Composition
| 1 | Healthcare | 85.27% |
| 2 | Materials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
| $33.2M | 9.36% | 360,000 | – | – |
|
|
MYOK
2
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $24M | 6.78% | 560,000 +165,000 | +42% | +$7.07M |
|
|
3
Alnylam Pharmaceuticals
ALNY
$58.5B
| $23.5M | 6.64% | 200,000 +95,000 | +90% | +$11.2M |
|
4
Sangamo Therapeutics
SGMO
$157M
| $21M | 5.93% | 1,400,000 | – | – |
|
|
BPMC
5
DELISTED
Blueprint Medicines
BPMC
| $20.8M | 5.86% | 298,000 +23,000 | +8% | +$1.6M |
|
|
BLUE
6
DELISTED
bluebird bio
BLUE
| $19.9M | 5.62% | 145,000 +80,000 | +123% | +$11M |
|
|
FMI
7
DELISTED
Foundation Medicine, Inc.
FMI
| $19.3M | 5.45% | 480,000 | – | – |
|
|
KITE
8
DELISTED
Kite Pharma, Inc.
KITE
| $19.1M | 5.38% | 106,000 +16,000 | +18% | +$2.88M |
|
|
ONCE
9
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $18.7M | 5.27% | 209,474 +39,474 | +23% | +$3.52M |
|
10
Agios Pharmaceuticals
AGIO
$2.19B
| $17M | 4.81% | 255,000 | – | – |
|
11
Voyager Therapeutics
VYGR
$186M
| $16.8M | 4.74% | 815,000 +75,000 | +10% | +$1.54M |
|
|
SAGE
12
DELISTED
Sage Therapeutics
SAGE
| $15M | 4.22% | 240,000 -15,000 | -6% | -$935K |
|
|
GNMK
13
DELISTED
GenMark Diagnostics, Inc
GNMK
| $14.4M | 4.08% | 1,500,000 +815,000 | +119% | +$7.85M |
|
14
Evolent Health
EVH
$1.12B
| $14.2M | 4% | 795,000 +275,000 | +53% | +$4.9M |
|
|
GBT
15
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $11.8M | 3.33% | 380,000 +165,000 | +77% | +$5.12M |
|
|
BOLD
16
DELISTED
Audentes Therapeutics, Inc
BOLD
| $11.2M | 3.16% | 400,000 | – | – |
|
|
CLVS
17
DELISTED
Clovis Oncology, Inc.
CLVS
| $10.5M | 2.97% | 127,500 -2,500 | -2% | -$206K |
|
18
Codexis
CDXS
$246M
| $9.81M | 2.77% | 1,475,000 +285,000 | +24% | +$1.9M |
|
19
Illumina
ILMN
$15.8B
| $8.77M | 2.47% | 44,000 +12,500 | +40% | +$2.49M |
|
|
JNCE
20
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $6.23M | 1.76% | 399,825 +239,825 | +150% | +$3.74M |
|
|
TSRO
21
DELISTED
TESARO, Inc.
TSRO
| $4.97M | 1.4% | 38,500 -9,500 | -20% | -$1.23M |
|
|
SYRS
22
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $3.77M | 1.06% | 256,215 +74,074 | +41% | +$1.09M |
|
23
CytomX Therapeutics
CTMX
$336M
| $3.23M | 0.91% | 177,500 | – | – |
|
24
Editas Medicine
EDIT
$231M
| $3.2M | 0.9% | 133,333 | – | – |
|
25
Fate Therapeutics
FATE
$120M
| $2.18M | 0.62% | 550,000 | – | – |
|